Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
BABA Alibaba Group Holding Ltd
OBMP OncBioMune Pharmaceuticals Inc
AVNW Aviat Networks Inc
AMPY Amplify Energy Corp
JEPI JPMorgan Equity Premium Income ETF
VOLAF Volvo AB
AGNC Agnc Investment Corp
GME GameStop Corp
HMNKF HMS Networks AB
Go

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Closing Price
$107.91
Day's Change
1.02 (0.95%)
Bid
--
Ask
--
B/A Size
--
Day's High
108.55
Day's Low
107.14
Volume
(Above Average)
Volume:
8,207,672

10-day average volume:
7,055,703
8,207,672

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ocugen, Inc. - OCGN

11:54 pm ET January 25, 2021 (Newsfile) Print

New York, New York--(Newsfile Corp. - January 25, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc.("Ocugen" or the "Company") (NASDAQ: OCGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Ocugen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On January 12, 2021, Ocugen issued a press release announcing the cancelation of a Company stockholder meeting previously scheduled for January 13, 2021, the following day. The press release stated that "[t]he Company plans to reevaluate the details of" a proposed share increase "in light of the recent potential addition of COVAXINT to its pipeline as well as its compliance with Nasdaq's Listing Rule 5550(a)(2)."

On this news, Ocugen's stock price fell $0.26 per share, or 10.44%, to close at $2.23 per share on January 12, 2021.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

888-476-6529 ext. 7980

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/72836

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.